9 Meters Biopharma, Inc. (NASDAQ:NMTR) has received a consensus rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $5.00.
A number of research firms recently commented on NMTR. William Blair reiterated a “buy” rating on shares of 9 Meters Biopharma in a report on Thursday, September 24th. Zacks Investment Research upgraded shares of 9 Meters Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, November 24th. Maxim Group began coverage on shares of 9 Meters Biopharma in a report on Friday, October 30th. They issued a “buy” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of 9 Meters Biopharma in a report on Monday, September 21st.
Hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC raised its holdings in shares of 9 Meters Biopharma by 775.4% during the third quarter. Steward Partners Investment Advisory LLC now owns 34,332 shares of the company’s stock valued at $28,000 after acquiring an additional 30,410 shares during the period. Virtu Financial LLC acquired a new stake in shares of 9 Meters Biopharma during the third quarter valued at approximately $31,000. Janney Montgomery Scott LLC raised its holdings in shares of 9 Meters Biopharma by 73.9% during the third quarter. Janney Montgomery Scott LLC now owns 40,000 shares of the company’s stock valued at $33,000 after acquiring an additional 17,000 shares during the period. Lindbrook Capital LLC acquired a new stake in shares of 9 Meters Biopharma during the third quarter valued at approximately $33,000. Finally, Regentatlantic Capital LLC raised its holdings in shares of 9 Meters Biopharma by 244.4% during the third quarter. Regentatlantic Capital LLC now owns 41,322 shares of the company’s stock valued at $34,000 after acquiring an additional 29,322 shares during the period. Institutional investors and hedge funds own 18.43% of the company’s stock.
Shares of NASDAQ:NMTR traded down $0.03 during trading on Friday, reaching $0.89. The company had a trading volume of 26,347 shares, compared to its average volume of 4,174,274. The business’s fifty day moving average is $0.89. 9 Meters Biopharma has a twelve month low of $0.44 and a twelve month high of $1.19.
9 Meters Biopharma (NASDAQ:NMTR) last issued its quarterly earnings results on Saturday, November 14th. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). Equities analysts forecast that 9 Meters Biopharma will post 0.07 earnings per share for the current fiscal year.
About 9 Meters Biopharma
9 Meters Biopharma, Inc, a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease.
Further Reading: How do investors use RSI to grade stocks?